RECRUITING

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to learn more about how low-resistance training impacts frailty and the quality of life of people with pulmonary arterial hypertension (PAH). Low-resistance training is an evidence-based approach that may help patients improve their functional ability.

Official Title

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

Quick Facts

Study Start:2024-09-04

Study Completion:2025-10-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06543745

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Diagnosis of PAH: idiopathic, heritable, associated with connective tissue disease, congenital heart disease, human immunodeficiency virus, drug- or toxin, or portopulmonary hypertension * On stable PAH therapy for 3 months	* World Health Organization (WHO) functional class IV * Left ventricular ejection fraction \< 40% (via transthoracic echocardiogram (TTE) within one year of screening) * Moderate or severe concomitant lung disease: Chronic Obstructive Pulmonary Disease (COPD) or interstitial lung disease * Enrollment in a clinical trial * Recent hospitalization (within 4 weeks of screening) * Inability to perform the Short Physical Performance Battery or wheelchair bound

Inclusion Criteria

Exclusion Criteria

* Diagnosis of PAH: idiopathic, heritable, associated with connective tissue disease, congenital heart disease, human immunodeficiency virus, drug- or toxin, or portopulmonary hypertension
* On stable PAH therapy for 3 months

* World Health Organization (WHO) functional class IV
* Left ventricular ejection fraction \< 40% (via transthoracic echocardiogram (TTE) within one year of screening)
* Moderate or severe concomitant lung disease: Chronic Obstructive Pulmonary Disease (COPD) or interstitial lung disease
* Enrollment in a clinical trial
* Recent hospitalization (within 4 weeks of screening)
* Inability to perform the Short Physical Performance Battery or wheelchair bound

Contacts and Locations

Study Contact

Zara Dunefsky, BA

CONTACT

215-294-9755

zara.dunefsky@pennmedicine.upenn.edu

Rebecca Gallagher, MSEd

CONTACT

215-662-4088

rebecca.lang@pennmedicine.upenn.edu

Principal Investigator

Nadine Al-Naamani, MD, MS

PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Study Locations (Sites)

University of Pennsyvania

Philadelphia, Pennsylvania, 19103

United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

Nadine Al-Naamani, MD, MS, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-04

Study Completion Date2025-10-01

Study Record Updates

Study Start Date2024-09-04

Study Completion Date2025-10-01

Terms related to this study

Additional Relevant MeSH Terms

Pulmonary Arterial Hypertension
Frailty